Patents Examined by Joseph Fischer
-
Patent number: 8940297Abstract: One aspect of the invention contemplates a mutant E-WE thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence. Another aspect contemplates a thrombin precursor that contains the amino acid residue sequence Asp/Glu-Gly-Arg at positions 325, 326 and 327 based on the preprothrombin sequence. A third aspect contemplates a thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence as well as the amino acid residue sequence Asp/Glu Gly Arg at positions 325, 326 and 327 based on the preprothrombin sequence. Also contemplated is a composition that contains an effective amount of mutant thrombin dissolved or dispersed in a pharmaceutically acceptable carrier. A method is also disclosed for enhancing treating and preventing thrombosis in a mammal in need using that composition.Type: GrantFiled: December 20, 2011Date of Patent: January 27, 2015Assignee: Saint Louis UniversityInventors: Enrico Di Cera, Andras Gruber, Prafull Gandhi, Leslie Pelc, Nicola Pozzi, David Collier Wood
-
Patent number: 8921066Abstract: Bio-adhesive compositions that include an extra-cellular matrix protein, bovine serum albumin conjugated with a fluorophore, and an aggregate are provided. The bio-adhesive composition may also include at least one component selected from the group consisting of collagen type IV, laminin, and chitosan. Also provided are methods of making the present compositions, that include taking a desired amount of extracellular matrix gel to liquid form of extracellular matrix; adding a desired amount of bovine serum albumin conjugated with a fluorophore; adding a desired amount of aggregate; and mixing. Further provided are methods for attaching cells to an apparatus using the present bio-adhesive compositions, and methods of attaching the present bio-adhesive compositions to an apparatus. Also provided are kits that include the present composition, components thereof or apparatuses, having the present composition attached thereto.Type: GrantFiled: August 3, 2011Date of Patent: December 30, 2014Assignee: University of Maryland, BaltimoreInventors: Christopher Ward, William J. Lederer, Benjamin L. Prosser
-
Patent number: 8916679Abstract: Provided are peptides that bind to the thymidylate synthase protein, in particular to human thymidylate synthase (hTS) protein, for the treatment of cancer. Further provided are peptides that can bind at a binding site located at the interface of thymidylate synthase protein. These peptides range from 3 to 10, preferably 4-8 amino acids and have a sequence that binds to each subunit of the thymidylate synthase dimer at the level of dimer interface, stabilizing the dimeric inactive form of the thymidylate synthase enzyme. In addition, provided are pharmaceutical compositions including these compounds as active agents, and uses thereof for the treatment of cancer and to reverse or/and be active in cancer drug resistance.Type: GrantFiled: December 1, 2009Date of Patent: December 23, 2014Assignees: Universita′ degli Studi di Modena e Reggio Emilia, Heidelberg Institute For Theoretical Studies (Hits)Inventors: Maria Paola Costi, Gaetano Marverti, Daniela Cardinale, Alberto Venturelli, Stefania Ferrari, Glauco Ponterini, Stefan Henrich, Outi Salo-Ahen, Rebecca Wade
-
Patent number: 8859490Abstract: Disclosed is a peptide nucleic acid monomer as well as a corresponding peptide nucleic acid molecule. The monomer comprises a terminal amino group and a terminal group A. The terminal amino group and the terminal group A are connected by an aliphatic moiety. The main chain of this aliphatic moiety is free of groups that are charged under physiological conditions. The terminal group A is one of —COOH, —COOR3, —COX, —COSR3, —CN, —CONH2, —CONHR3, —CONR3, R4, with R3 and R4 being H or an aliphatic, alicyclic, aromatic, arylaliphatic or arylalicyclic group, and X being a halogen atom. The terminal amino group is substituted by an aliphatic group with a main chain of at least two carbon atoms and optionally 0 to about 2 heteroatoms selected from the group N, O, S, Se and Si. The main chain has a polar head group Z.Type: GrantFiled: September 3, 2008Date of Patent: October 14, 2014Assignee: Nanyang Technological UniversityInventors: Chuan Fa Liu, Yun Zeng, Xiao Wei Lu
-
Patent number: 8802818Abstract: Prostaglandin-F2 alpha (PGF2?) receptor (FP) modulators of formula I, as well as the use of PGF2? receptor modulators for the treatment of conditions associated with FP activity such as preterm labor and colorectal cancer, are disclosed.Type: GrantFiled: June 1, 2012Date of Patent: August 12, 2014Inventors: William D. Lubell, Sylvain Chemtob, Terence E. Hebert, Audrey Claing, Stephane Laporte, Carine B. Bourguet, Eugenie Goupil, Xin Hou, Danae Tassy
-
Patent number: 8785373Abstract: Methods and pharmaceutical compositions for the treatment of cancer or acute ischemia are provided. Also provided are methods of identifying agents capable of preventing the formation of or dissociating the MSF-A-HIF-1alpha protein complex, and methods of determining the prognosis of an individual having cancer by identifying the presence or absence of such a protein complex.Type: GrantFiled: February 6, 2012Date of Patent: July 22, 2014Assignee: The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterInventor: Nicola J. Mabjeesh
-
Patent number: 8778870Abstract: Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.Type: GrantFiled: November 3, 2011Date of Patent: July 15, 2014Assignee: Catalyst Biosciences, Inc.Inventors: Edwin L. Madison, Christopher Thanos, Grant Ellsworth Blouse
-
Patent number: 8765672Abstract: The present invention relates to a method of modulating a release of biomolecules having heparin-binding affinity, and more specifically, to a method of modulating a release of biomolecules having heparin-binding affinity, using thiolated heparin adsorbed on metal surface. According to the present invention, it is possible to modulate various biomolecules having heparin-binding affinity such as growth factors spatiotemporally by external electrical stimulations, without causing cytotoxicity and having deteriorating effects on cell activity. Thus, the present invention can be applied for various biomedical and biotechnical fields including drug delivery, biosensor, and cell culture.Type: GrantFiled: July 16, 2012Date of Patent: July 1, 2014Assignee: Gwangju Institute of Science and TechnologyInventors: Giyoong Tae, Bo-young Kim, Kihak Gwon, Young Ha Kim, Myung-Han Yoon
-
Patent number: 8748451Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.Type: GrantFiled: April 22, 2013Date of Patent: June 10, 2014Assignee: The Board of Trustees of The University of IllinoisInventors: Alan Kozikowski, Kyle Vincent Butler, Jay Hans Kalin
-
Patent number: 8716438Abstract: Chemoattractant polypeptide compounds for progenitor cells and compositions and drug products comprising the compounds are provided herein. Methods for attracting progenitor cells to a location in or on a patient also are provided along with methods of growing and repairing bone.Type: GrantFiled: October 8, 2010Date of Patent: May 6, 2014Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Vineet Agrawal, Stephen F. Badylak, Scott Alan Johnson, Stephen Tottey
-
Patent number: 8716436Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: GrantFiled: May 22, 2012Date of Patent: May 6, 2014Assignees: The Administrators of the Tulane Educational Fund, U.S. Department of Veterans AffairsInventors: James E. Zadina, Laszlo Hackler
-
Patent number: 8703913Abstract: The invention relates to an ADP binding molecule comprising a polypeptide, said polypeptide comprising amino acid sequence corresponding to at least amino acids 11 to 310 of SEQ ID NO:1, wherein said polypeptide comprises a substitution relative to SEQ ID NO:1 at amino acid C287, and wherein said polypeptide comprises a further cysteine residue for attachment of at least one reporter moiety, and wherein said polypeptide has at least 68% sequence identity to SEQ ID NO:1 at the amino acid residues corresponding to those shown in column III of table A.Type: GrantFiled: September 15, 2009Date of Patent: April 22, 2014Assignee: Medical Research CouncilInventors: Martin Webb, Simone Kunzelmann
-
Patent number: 8658593Abstract: Pharmaceutical compositions are provided. The compositions comprise a compound comprising the hyaluronan-containing structure A-(low molecular weight hyaluronan domain)-B. The compositions also comprise a pharmaceutically acceptable excipient. A is hydrogen, a substituent that does not comprise a binding site for tumor necrosis factor stimulated gene-6 (“TSG-6”) protein, a substituent that interferes with binding of TSG-6 protein immediately adjacent thereto, or chondroitin. B is hydroxyl, a substituent that does not comprise a binding site for TSG-6 protein, a substituent that interferes with binding of TSG-6 protein immediately adjacent thereto, or chondroitin. The composition is suitable for administration by injection, inhalation, topical rub, or ingestion.Type: GrantFiled: June 6, 2012Date of Patent: February 25, 2014Assignee: The Cleveland Clinic FoundationInventors: Anthony Calabro, Mark Lauer, Vincent Hascall
-
Patent number: 8598312Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.Type: GrantFiled: June 15, 2012Date of Patent: December 3, 2013Assignee: Provid Pharmaceuticals, Inc.Inventors: Gary Lee Olson, Charles Michael Cook, Christopher Raymond Self
-
Patent number: 8569238Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.Type: GrantFiled: March 18, 2013Date of Patent: October 29, 2013Assignees: The Chemo-Sero-Therapeutic Research Institute, Ginkyo Academy Kumamoto Health Science University, National University Corporation Kumamoto UniversityInventors: Shintaro Kamei, Asami Shindome, Takayoshi Hamamoto, Hiroaki Maeda, Masaki Hirashima, Sachio Okuda, Misako Umehashi, Sachie Ogawa, Megumi Imuta, Norio Akaike, Kazuo Takahama, Ryoko Wada